Next Article in Journal
Stability Evaluation of Extemporaneously Compounded Vancomycin Ophthalmic Drops: Effect of Solvents and Storage Conditions
Next Article in Special Issue
Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation
Previous Article in Journal
Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment
Previous Article in Special Issue
Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography
Open AccessReview

Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases

Clearside Biomedical, 900 North Point Parkway, Suite 200, Alpharetta, GA 30005, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Anuj Chauhan
Pharmaceutics 2021, 13(2), 288; https://doi.org/10.3390/pharmaceutics13020288
Received: 25 December 2020 / Revised: 7 February 2021 / Accepted: 8 February 2021 / Published: 22 February 2021
(This article belongs to the Special Issue Recent Advances in Ophthalmic Drug Delivery)
Suprachoroidal drug delivery technology has advanced rapidly and emerged as a promising administration route for a variety of therapeutic candidates, in order to target multiple ocular diseases, ranging from neovascular age-related macular degeneration to choroidal melanoma. This review summarizes the latest preclinical and clinical progress in suprachoroidal delivery of therapeutic agents, including small molecule suspensions, polymeric entrapped small molecules, gene therapy (viral and nonviral nanoparticles), viral nanoparticle conjugates (VNCs), and cell therapy. Formulation customization is critical in achieving favorable pharmacokinetics, and sustained drug release profiles have been repeatedly observed for multiple small molecule suspensions and polymeric formulations. Novel therapeutic agents such as viral and nonviral gene therapy, as well as VNCs, have demonstrated promise in animal studies. Several of these suprachoroidally-administered therapies have been assessed in clinical trials, including small molecule suspensions of triamcinolone acetonide and axitinib, viral vector RGX-314 for gene therapy, and VNC AU-011. With continued drug delivery research and optimization, coupled with customized drug formulations, suprachoroidal drug delivery may address large unmet therapeutic needs in ophthalmology, targeting affected tissues with novel therapies for efficacy benefits, compartmentalizing therapies away from unaffected tissues for safety benefits, and achieving durability to relieve the treatment burden noted with current agents. View Full-Text
Keywords: suprachoroidal; microinjector; ocular drug delivery; suprachoroidal space (SCS); gene therapy; anti-VEGF; macular degeneration; glaucoma suprachoroidal; microinjector; ocular drug delivery; suprachoroidal space (SCS); gene therapy; anti-VEGF; macular degeneration; glaucoma
Show Figures

Figure 1

MDPI and ACS Style

Wan, C.-r.; Muya, L.; Kansara, V.; Ciulla, T.A. Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases. Pharmaceutics 2021, 13, 288. https://doi.org/10.3390/pharmaceutics13020288

AMA Style

Wan C-r, Muya L, Kansara V, Ciulla TA. Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases. Pharmaceutics. 2021; 13(2):288. https://doi.org/10.3390/pharmaceutics13020288

Chicago/Turabian Style

Wan, Chen-rei; Muya, Leroy; Kansara, Viral; Ciulla, Thomas A. 2021. "Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases" Pharmaceutics 13, no. 2: 288. https://doi.org/10.3390/pharmaceutics13020288

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop